Rheumatoid arthritis adjunctive care, defined: what sits alongside DMARDs and biologics, why your rheumatologist stays in charge, and what we send them.
"Adjunctive" sounds like hedging. It is closer to a constraint. The word means a treatment is added to an established one with the established one left completely intact, and in rheumatoid arthritis that distinction carries more weight than in almost anything else we are asked about.
RA erodes joints, and it does so early. The reason rheumatology moved toward treating hard and treating to a target is that erosion does not reverse once it has happened; time spent on inadequate disease control is time you do not get back. Any care arranged around that treatment has to be built so it cannot interfere with it.
In practice, adjunctive means four things at once. Your prescribed therapy continues unchanged and on schedule. Your rheumatologist keeps ownership of the disease. Anything we do is documented and sent to them. And if the two ever appear to conflict, the disease-modifying therapy wins, every time.
It also rules things out. We do not review your diagnosis, we do not offer an opinion on whether your biologic is the right one, and we do not describe any protocol as an alternative to it. If you came here hoping to hear that regenerative medicine could get you off methotrexate, that is not something this clinic will tell you, and you should be wary of one that does.
Rheumatoid arthritis is one of the few chronic conditions with a genuinely disciplined management model behind it. Disease activity is scored, medication is escalated or held on the basis of that score, bloods are monitored for drug toxicity, and imaging checks whether joints are being protected. It is a feedback loop, and feedback loops break when unrecorded variables enter them.
There is a safety layer as well. Most RA therapy works by damping immune function, which raises infection risk and makes the timing of doses around illness, surgery and vaccination a clinical decision rather than an administrative one. A clinician adding anything described as acting on immune signalling has an obligation to tell the person managing that risk. The broader picture of inflammation that will not resolve is worth reading alongside this.
Two protocols, described plainly. Molecular hydrogen is delivered by inhalation through a soft nasal cannula, typically 20 to 40 minutes a session, two or three times a week for a four to six week starter course, with hydrogen water between sessions. H₂ is understood to act as a selective antioxidant, tempering the most reactive oxidants while leaving milder signalling species largely alone; the device specifications and routes are set out on the molecular hydrogen page.
Ultra RSF (Regenerative Signaling Factors) is an acellular concentrate of more than 300 proteins and growth factors drawn from all six regions of the placenta, screened under 21 CFR 1271.55 and characterised by sequencing and mass spectrometry. It is not a stem-cell therapy: no live cells, no DNA, no RNA. Routes include intravenous, intra-articular, subcutaneous and intra-nasal, and which one is used, if any, is a physician's decision made case by case. How the material is made is described in full elsewhere on the site.
What those two paragraphs do not contain is a claim. Neither protocol treats rheumatoid arthritis, controls disease activity, slows erosion or induces remission, and nobody has the trial evidence that would be needed to say otherwise. They are described as supporting immune balance, barrier integrity and tissue repair, which is a statement about biology under study, not about your joint count.
Coordination only means something if it is written down. With your consent, the physicians treating your RA get a note they can file, not a phone call they have to summarise.
With one of our medical providers, online from anywhere or in person at either Orlando-area office. Bring your diagnosis, your current medications and doses, and any recent labs or imaging reports.
Our physician reviews the drivers behind your symptoms, assesses severity, and decides whether adjunctive care is reasonable in your case. Sometimes the answer is that it is not.
If a plan is issued, it goes to you and to the physicians managing your condition. Nothing is administered on the strength of a conversation alone.
In-home or in-clinic, on a defined rhythm, with your rheumatologist continuing to monitor disease activity exactly as before. More detail on the sequence is in what happens in a free consultation.
What the consultation is not: a second opinion, a diagnostic service, a prescription review, or a sales appointment with a package attached to the end of it. If you want a different read on your RA management, the person to ask is another rheumatologist.
Some people are told that adjunctive care is not appropriate for them, or not yet. Uncontrolled disease belongs with the specialist first. An active infection, a recent change in therapy, or a plan that seems to be a way of avoiding a treatment decision are all reasons to wait or to decline outright.
That answer is a reasonable thing to expect from any clinic in this field, and its absence tells you something. If everyone who calls is a candidate, the evaluation is not an evaluation.
No. Disease-modifying therapy is the treatment for rheumatoid arthritis and adjunctive care does not substitute for it at any dose or stage. No prescribed medication should be stopped or reduced except on your rheumatologist's direction.
Yes, and with your consent we write to them ourselves. It matters most around infection risk and the timing of biologic doses, which is why the coordination is a requirement rather than a nicety.
Intra-articular delivery is one of the routes a physician may use, and whether it is appropriate is decided case by case. It is not a treatment for rheumatoid arthritis and does not affect the systemic disease process your medication is prescribed to control.
Contact your rheumatologist rather than us. A flare is a disease-activity question and it belongs with the specialist who manages your treat-to-target plan.
No. It is acellular, DNA-free and RNA-free, delivering the signalling proteins cells release rather than the cells themselves. Any clinic describing it as stem-cell treatment has the category wrong.
This article is general health information, not medical advice, and does not create a physician–patient relationship. It describes mechanisms reported in the literature rather than guaranteed outcomes; individual response varies. Regen MDs provides you an alternative to your current care, and is complementary to your guideline-based medical care. Ultra RSF (Regenerative Signaling Factors) is not a stem-cell therapy. Talk to a licensed clinician before starting, stopping, or changing any treatment.
Resolution is an active phase of healing, not the absence of one. When it fails to arrive, inflammation idles — and that pattern sits underneath most autoimmune disease.
A stage-by-stage account of the first call — who is on it, what gets decided later, and the cases we turn away.
Three preparations, three different contents — and a market that blurs them on purpose. A composition-by-composition comparison, with no outcome claims attached.
Thirty minutes with one of our physicians — no cost, no obligation — to review your history and set out the options honestly.